Our Board currently consists of eleventen members who, in accordance with our certificate of incorporation and bylaws, are divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election.
Biographical information regarding the business experience of each of our directors and the primary aspects of each of our directors’ experience, qualifications, attributes or skills that led to the conclusion that each of our directors should serve on our Board is set forth below:
Nominees for Class III Directors for a Term Expiring at the 20252026 Annual Meeting
Stanley S. Trotman, Jr. | | | 2021 | | | 78 | | | ✔ | | | Director | | | ✔ | | | ✔ | | | |
Kristiina Vuori, M.D., Ph.D. | | | 2021 | | | 54 | | | ✔ | | | Director | | | | | | ✔ | | | |
Martin Wygod | | | 2021 | | | 82 | | | | | | Director | | | | | | | | | |
Mark J. Adler, M.D. | | | 2021 | | | 66 | | | ✔ | | | Director | | | | | | ✔ | | | |
Jennifer Hajj | | | 2021 | | | 39 | | | ✔ | | | Director | | | | | | | | | ✔ |
Shahir Kassam-Adams | | | 2021 | | | 63 | | | ✔ | | | Director | | | ✔ | | | | | | ✔ |
Stanley S. Trotman, Jr.Mark J. Adler, M.D. has served as a Class III director since the closing of the business combination in March 2021. Prior to that time, Dr. Adler was a member of WebMD’s Board of Directors from 2000 to 2017. Since 2004, Mr. Trotman2014, Dr. Adler has beenalso served as Strategic Advisor to, and as a member of the presidentScientific Advisory Board of, Jupiter Private Equity LLC. Mr. Trotman retired in 2001 from UBS Financial Services,Biological Dynamics, Inc. after its 2000 acquisition, a privately held biotechnology company, and is currently the Chairman of PaineWebber Incorporated, an investment banking firm where he had been a Managing Director with the Health Care Group since 1995. Mr. Trotman wasthat Scientific Advisor Board. He is also currently a director of WebMD from 2005the San Diego Cancer Research Institute. From February 2011 until its sale to KKR in 2017. From 2000 until his resignation in 2019, Mr. TrotmanFebruary 2014, Dr. Adler served as Director of Strategic Development for UC San Diego Oncology. Dr. Adler, an oncologist, was a directorco-founder of American Shared Hospital Services, a public company that provides radio surgery services to medical centersthe San Diego Cancer Center and served for useover 10 years as its Chief Executive Officer until February 2011. Until April 2006, Dr. Adler had served, for more than five years, as the Chief Executive Officer of the combined internal medicine and oncology group of Medical Group of North County in brain surgery.San Diego, California.
Mr. Trotman’sDr. Adler’s qualifications for membership on our Board include his many years of experience as a physician and an executive of a physician practice, his involvement with early-stage biotechnology companies and his prior service as a director of other public companies, including WebMD, and private companies in various aspects of the healthcare industry and his experience as an investment banker specializing in healthcare companies.
Kristiina Vuori, M.D., Ph.D.Jennifer Hajj has served as a Class III director since the closing of the business combination in March 2021. Dr. VuoriMs. Hajj has been the Head of Partnerships at Galileo Inc. since March 2019. Galileo is a physician-scientist with background in biomedical research and drug discovery, and as an educator of research scientists. She has experience in managing a large non-profit research organization, and has held various leadership roles in non-profit, for-profit and public boards. Since January 2010, Dr. Vuori has served as President and member ofprivately-held healthtech startup that enables the Board of Directors of Sanford Burnham Prebys Medical Discovery Institute (SBP), one of the largest non-profit biomedical research centers in the U.S. with a focus on cancer, neurodegeneration, inflammatory and infectious diseases, heart disease and rare children’s disorders. Since January 1995, Dr. Vuori has alsodoctor-patient relationship. From May 2006 to February 2019, Ms. Hajj served as a Professor at SBP’s National Cancer Institute-designated Cancer Center. Previously, she served as SBP’s EVP for Scientific Affairssenior expert on New York State Medicaid policy and government programs across Sachs Policy Group’s (SPG) client base and led SPG’s innovation practice. Ms. Hajj joined SPG in 2008-2010, as Director2006 and consulted with a diverse set of clients including hospitals, long-term care systems, physician groups, health and human service agencies, health plans, tech-enabled companies and startups. Areas of specialization included public policy, strategic planning, program design, reimbursement, regulatory environments, technology and implementation. Subject matter expertise included, but was not limited to: Medicaid, DSRIP, managed care, value-based payments, behavioral health, long-term care, vulnerable populations and social determinants of health. In 2013, Ms. Hajj led the Cancer Centerfirm’s expansion to digital health and innovation. She led SPG’s innovation practice and actively advised and mentored several health care startups and entrepreneurs. Her expertise includes strategy, product development, market dynamics, business development, partnerships, regulatory environments and public policy. Ms. Hajj received her B.A. in 2005-2013,public health studies with departmental honors distinction from the Johns Hopkins University, her M.P.H. from Columbia University Mailman School of Public Health and as Deputy Director of the Cancer Center in 2003-2005. Dr. Vuori currently serves or has served on the Board of Directors for American Association for Cancer Research, California Institute for Regenerative Medicine, California Breast Cancer Research Program, Sanford Consortium for Regenerative Medicine, UCSD Sanford Stem Cell Clinical Center, Bionano Genomics, Inc, Inhibrx, Inc. and Sio Gene Therapies, Inc. She was director of WebMD, Inc.her M.B.A. from 2104 until it was sold to KKR in 2017. Dr. Vuori holds M.D. and Ph.D. degrees from University of Oulu, Finland.Columbia Business School.
Dr. Vuori’sMs. Hajj’s qualifications for membership on our Board include her many years of experience as a physician-scientistdirector and an executiveadvisor of a prestigious medical institution, her involvement with early-stage biotechnology and medicalother companies in various aspects of the healthcare industry and her prior serviceexperience as a director ofan expert in public companies.health and healthcare strategy.
Martin J. WygodShahir Kassam-Adams has served as a Class III director since the closing of the business combination in March 2021. Mr. Wygod previously servedKassam-Adams was a co-Founder and Chief Executive Officer of Universal Patient Key, which was recapitalized as a Manager of Medical Outcomes Research Analytics, LLC,Datavant in 2018. In addition to founding multiple healthcare technology companies, Mr. Kassam-Adams has been an early investor or MOR, from August 2019 until February 2021. Mr. Wygod served as Executive Chairman of WebMD Health Corp from May 2005 to September 2017, when WebMD was sold for $2.8 billion to Internet Brands, a KKR portfolio company. Mr. Wygod also served as Chairman of the Board of HLTH Corporation from March 2001 to October 2009 when the merger of HLTH Corporation and WebMD Health Corporation was completed.operating executive in multiple healthcare technology-enabled